The Shiseido Beauty Innovations Fund has announced an investment of RMB100m in Jiangsu Trautec Medical Technology, a China-based supplier of recombinant collagen 2-based biomaterials.
The fund was co-established by the Japanese cosmetics group’s China subsidiary, Shiseido China Co Ltd, and Boyu Capital; this investment marks its first in Trautec, in which it is the lead investor.
Shiseido will additionally form a strategic partnership with Trautec to collaborate in areas such as R&D, raw material supply and sales channels to accelerate breakthroughs in functional skin care.
Established in 2015, Trautec operates a production plant located in Changzhou, Jiangsu Province.
It holds multiple intellectual property rights in the development of recombinant collagen.
According to Shiseido, the market for functional skin care is growing significantly in the region with more Chinese consumers looking for effective solutions to their skin problems.
Recombinant collagen’s use, meanwhile, is expanding because of its stability and effectiveness in the cosmetic and medical fields.
